Glutamatergic transmission in schizophrenia:  from basic research to clinical practice.
OBJECTIVE
The past 20 years have seen the glutamatergic hypothesis go from theory to phase III trials of novel mechanism antipsychotics.


RESULTS
We review the recent literature on glutamatergic theory, covering assessment and genetic studies, as well as drug development in animals and humans.


CONCLUSIONS
Although evidence continues to accumulate in support of glutamate hypotheses, further research continues to be required and interactions with other key systems need to be explored.
Schizophrenia Research Institute, Nathan Kline Institute for Psychiatric Research, New York, USA. jkantrowitz@nki.rfmh.org
Joshua
J
Kantrowitz
Daniel C
DC
Javitt
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D002986:Clinical Trials as Topic; D018698:Glutamic Acid / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D013788:Thalamus / Q000378:metabolism
D014150:Antipsychotic Agents; D015415:Biomarkers; D016194:Receptors, N-Methyl-D-Aspartate; D018698:Glutamic Acid